I’ll raise you: How about a clinical trial? We have engineered a super long acting and potent anti-IL11 for human ageing trials at vvb.bio. Faster to humans, not another 5 years in mice Needs investment, build out, approvable endpoints and not easy ++. But..

A timely reminder about a key interest in the Proactive Health office at ARPA-H is for innovative solutions to extend healthspan. Here is a call. sam.gov/opp/53707a1538…

What if a simple home test could save millions by catching cancer early? POSEIDON will develop 1st-in-class, synthetic Multi-Cancer-Early Detection tests for sensitive/specific stage 1 detection of 30 solid tumors using only breath and/or urine samples. arpa-h.gov/news-and-event…

We’re GLIDE-ing into a new program to transform lymphatic medicine! Groundbreaking Lymphatic Interventions & Drug Exploration (GLIDE) will develop cutting-edge interventions for chronic conditions linked to lymphatic dysfunction. Proposers' Day is 9/17! arpa-h.gov/research-and-f…

Attention folks in oncology, biopharma, biotech, medtech & health tech! We launched POSEIDON, a program to develop at-home Multi-Cancer-Early Detection tests, and now we're inviting you to a day of learning in Baltimore next month (Sept. 4)! Register now: solutions.arpa-h.gov/Events/POSEIDO…

NEW: Today in New Orleans, President Biden and Jill Biden will announce up to $150 million in ARPA-H awards to develop technologies that will allow surgeons to provide more successful tumor-removal surgeries for people facing cancer. (1/4) whitehouse.gov/briefing-room/…

Attention folks in oncology, biopharma, biotech, medtech & health tech! We launched POSEIDON, a program to develop at-home Multi-Cancer-Early Detection tests, and you're invited to a day of in-person learning on Sept. 4 in Baltimore. Register now! (1/3) solutions.arpa-h.gov/Events/POSEIDON

Aaron Levie 🇺🇸 Elon Musk Part of the misunderstanding of drug pricing is the impact of pharmacy benefit managers. Prior to Mark Cuban Cost Plus Drug Company publishing our price list, there was not a benchmark to compare prices. They made sure that every contract was opaque and under an NDA For instance, Box, Tesla,

New from the lab Impaired mitochondrial creatine metabolism during Duchenne muscular dystrophy seems to trigger increases in an alternative energy transfer pathway ('mitohormesis') Mito creatine metabolism is also improved by a mitochondrial therapeutic sciencedirect.com/science/articl…

This is aging therapeutic related: Is anyone else bored of academics with no skin in the game or experience, opining on how to develop drugs or allocate resources for an aging industry that helps people?

Our next Longevity SF event will be on Brain Aging after work on September 30th. Big thanks to BioAge for sponsoring, MBC BioLabs for use of their beautiful space, and Chris Patil for moderating. Hope to see some folks there! RSVP: lu.ma/90qqi0eu

Pairing aging research with clinical trial reform (expanded testing and use of aging-related biomarkers as potential surrogate endpoints for therapies) would be super interesting.

✨Excited to announce the upcoming Keystone Symposium on Aging: New Frontiers in Rejuvenation and Therapeutics. Co-organized with Morgan Levine and Dario Riccardo Valenzano🐟🦠🤌🏽! Join us in Breckenridge, CO Feb. 17-20, 2025!✨ keystonesymposia.org/conferences/co…

I’m looking forward to attending the ARDD Meeting. Happy to chat with folks about how ARPA-H can help build the train tracks for a longevity therapeutics industry. #ARDD2024

NEW: What if we could ensure AI models in health care autocorrected for peak performance? Announcing PRECISE-AI, our program to develop techniques to automatically identify and correct performance degradation of AI-enabled clinical decision support tools. arpa-h.gov/news-and-event…

a distinct disipline is emerging from the bio & ML intersection -- predictive biology - enabled by AI - understanding = prediction, not causal diagrams - emergent instead of reductionist - new institutions: industrial > academic a rough attempt at outlining the new field:

This is a huge validation of leveraging the biology of aging with smart clinical decision making.

NEW: Renee D. Wegrzyn’s #PowerOfIdeas essay for Milken Institute touches on our agency, which aims to make pivotal investments in high-risk, high-reward ideas that cannot be achieved through traditional research or investment. (1/2) milkeninstitute.org/content-hub/po…

Hard to believe our first full conference is just a couple months away, and sheesh, we get to do it at Harvard 😎 Can’t wait to see you there!

🎯 Our Mission Office-specific ISOs are driving change across health science, proactive health, resilient systems, and scalable solutions. Ready to lead the future of healthcare? Submit your proposal! arpa-h.gov/research-and-f…